Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects

Simple item page
dc.contributor.authorUsana Chatturong
dc.contributor.authorHélène Martin
dc.contributor.authorPerle Totoson
dc.contributor.authorKornkanok Ingkaninan
dc.contributor.authorPrapapan Temkitthawon
dc.contributor.authorSaharat Sermsenaphorn
dc.contributor.authorThanachon Somarin
dc.contributor.authorAdchatawut Konsue
dc.contributor.authorM. Paul Gleeson
dc.contributor.authorCéline Demougeot
dc.contributor.authorKrongkarn Chootip
dc.date.accessioned2026-05-08T19:17:52Z
dc.date.issued2022-9-24
dc.identifier.doi10.1016/j.vph.2022.107111
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/16232
dc.publisherVascular Pharmacology
dc.subjectPulmonary Hypertension Research and Treatments
dc.subjectRenin-Angiotensin System Studies
dc.subjectPhosphodiesterase function and regulation
dc.titleQuinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects
dc.typeArticle

Files

Collections

All